Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Gynecologic Oncology
•
Endometrial Cancer
•
Medical Oncology
Would you consider trying Pembrolizumab + Lenvatinib after progression on first-line Carboplatin + Paclitaxel + Immunotherapy for metastatic endometrial cancer?
Related Questions
What adjuvant treatment would you recommend for a patient with FIGO 2023 IIIB2 endometrioid endometrial adenocarcinoma (Grade 3, p53mut, MMR proficient), metastatic to the uterine serosa, bilateral ovaries, and anterior peritoneal reflection?
How would you sequence adjuvant chemo-immunotherapy (paclitaxel/carbo/pembro or paclitaxel/carbo/dostarlimab) with EBRT and vaginal cuff brachytherapy in advanced uterine cancer that meets clinical criteria for both EBRT and chemo-IO?
Do you screen for immune-related adrenal insufficiency for patients on immune checkpoint inhibitors?
Given the negative results of GOG-0238 but the positive results of the RUBY trial, how do you manage isolated vaginal cuff recurrence of endometrial cancer?
How would you manage a POLE mutated, p53 abnormal IA myoinvasive carcinosarcoma of the endometrium with no LVSI?
Would you add olaparib to maintenance immunotherapy for a patient with recurrent MMR-proficient, HER2-negative serous endometrial carcinoma?
What would you offer a patient with MSI-high metastatic endometrial cancer after disease progression on pembrolizumab?
Do you have a maximal limit to the number of pegylated doxorubicin cycles you will prescribe a patient for recurrent endometrial cancer?
When do you recommend adjuvant trastuzumab for completely resected uterine cancer and for how long do you give it?
Would you consider the addition of trabectedin to adjuvant doxorubicin in a patient with IVB leiomyosarcoma with completely resected disease (hysterectomy and thigh mass with negative margins)?
